At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 260 enrolled
Drug / intervention
Nepafenac Ophthalmic Suspension, 0.1% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical Evaluation of Safety and Efficacy of Nepafenac Ophthalmic Suspension, 0.1% Compared to Placebo for the Prevention and Treatment of Ocular Inflammation and Pain Associated With Cataract Surgery in Adult Chinese Subjects
In Brief
A Phase 3 clinical trial evaluating Nepafenac Ophthalmic Suspension, 0.1% and Nepafenac Vehicle Ophthalmic Solution for Cataract. Completed, enrolled 260 participants across 1 site.
Detailed Summary
The purpose of this study was to demonstrate that Nepafenac Ophthalmic Suspension, 0.1% is superior to Nepafenac Vehicle (placebo) for the prevention and treatment of ocular inflammation and pain associated with cataract surgery in Chinese subjects.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
CountriesChina
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedSep 2011
Primary CompletionApr 2012
TodayJul 2026
First PostedSep 1, 2011
Enrollment StartJul 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 14.8 years ago
Interventions
Nepafenac Ophthalmic Suspension, 0.1%drug
Topical ocular administration
Nepafenac Vehicle Ophthalmic Solutionother
Inactive ingredients used as placebo; topical ocular administration